<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627835</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-003</org_study_id>
    <nct_id>NCT00627835</nct_id>
  </id_info>
  <brief_title>Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)</brief_title>
  <official_title>A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses)&#xD;
      and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib,&#xD;
      cisplatin and radiation in the locally advanced squamous cell carcinomas of the head and neck&#xD;
      (SCCHN)patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Squamous cell carcinoma of the head and neck is a relatively common malignancy in both Canada&#xD;
      and the United States. Despite advancements made with the demonstration of improved outcomes&#xD;
      for concurrent platinum based chemotherapy with radical radiation in locally advanced SCCHN,&#xD;
      approximately 50% of cases will recur. The current treatment of locoregionally&#xD;
      recurrent/metastatic SCCHN is palliative in intent, with a median survival in this population&#xD;
      of 6-8 months. Thus improvements to the current backbone treatment of locally advanced SCCHN,&#xD;
      that is platinum based chemotherapy with radical radiation, are desperately needed.&#xD;
&#xD;
      This is a non-randomized, open-label, phase I dose escalation trial of neoadjuvant Sorafenib&#xD;
      and concurrent Sorafenib, Cisplatin and radiation in locally advanced squamous cell&#xD;
      carcinomas of the head and neck (SCCHN).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Site decided not to open this study&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of neoadjuvant BAY 43-9006 (sorafenib) and concurrent BAY 43-9006 with radiation in a cohort of SCCHN</measure>
    <time_frame>ongoing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MTD Maximal tolerated dose</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 1: sorafenib and radiation: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2:Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation</description>
    <arm_group_label>Treatment Group 1: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation</description>
    <arm_group_label>Treatment Group 1: sorafenib and radiation: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib and cisplatin</intervention_name>
    <description>Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7</description>
    <arm_group_label>Treatment Group 2: Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib and cisplatin</intervention_name>
    <description>o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7</description>
    <arm_group_label>Treatment Group 2: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib and cisplatin</intervention_name>
    <description>Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7</description>
    <arm_group_label>Treatment Group 2:Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria: Treatment Group 1 (Cohorts 1 &amp; 2) - Radiation and Sorafenib Only.&#xD;
&#xD;
          1. Previously untreated squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx. Histological or cytological confirmation is required. The&#xD;
             disease must be considered to be potentially curable with radiation only.&#xD;
&#xD;
          2. Stage III or IV disease (UICC/AJCC classification, 6th edition)&#xD;
&#xD;
          3. Age ≥18&#xD;
&#xD;
          4. Patients for whom concurrent cisplatinum is contraindicated due to poor patient&#xD;
             tolerance (significant weight loss &gt; 10% of body weight, mild renal dysfunction,&#xD;
             ototoxicity, neuropathy, or age &gt;70) yet deemed fit for radical radiation.&#xD;
&#xD;
          5. Signed written consent.&#xD;
&#xD;
          6. Availability for follow-up after treatment.&#xD;
&#xD;
          7. If the patient is fertile he/she is aware of the risk of becoming pregnant or&#xD;
             fathering children and will use adequate contraception (oral contraception, IUD,&#xD;
             diaphragm and spermicide or male condom and spermicide) throughout therapy and for at&#xD;
             least 2 weeks after therapy.&#xD;
&#xD;
          8. Life expectancy greater than 6 months&#xD;
&#xD;
        Inclusion Criteria: Treatment group 2 (Cohorts 3 to 5) - Radiation, Sorafenib and&#xD;
        Cisplatin.&#xD;
&#xD;
          1. Previously untreated squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx. Histological or cytological confirmation is required. The&#xD;
             disease must be considered to be potentially curable by combined chemoradiation.&#xD;
&#xD;
          2. Stage III or IV disease (UICC/AJCC classification, 6th edition)&#xD;
&#xD;
          3. Age ≥18.&#xD;
&#xD;
          4. Signed written consent.&#xD;
&#xD;
          5. Availability for follow-up after treatment.&#xD;
&#xD;
          6. If the patient is fertile, he/she is aware of the risk of becoming pregnant or&#xD;
             fathering children and will use adequate contraception (oral contraception, IUD,&#xD;
             diaphragm and spermicide or male condom and spermicide) throughout therapy and for at&#xD;
             least 3 months after therapy.&#xD;
&#xD;
          7. Life expectancy greater than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Treatment Group 1 (Cohorts 1 &amp; 2) - Radiation and Sorafenib Only.&#xD;
&#xD;
          1. ECOG performance status 3 or 4&#xD;
&#xD;
          2. Absolute neutrophil count &lt;1.0 X 109/L, platelet count &lt;100 X 109/L or hemoglobin &lt;90&#xD;
             g/L.&#xD;
&#xD;
          3. Serum bilirubin ≥1.5 times ULN or AST/ALT ≥ 2.5 times ULN.&#xD;
&#xD;
          4. Calculated creatinine clearance (Cockcroft-Gault) &lt;40 mL/min. For patients in whom the&#xD;
             calculated creatinine clearance is borderline, GFR may be estimated by nuclear&#xD;
             renogram with the creatinine clearance ≥ 40 mL/min to be eligible.&#xD;
&#xD;
          5. Uncontrolled hypertension despite adequate anti-hypertensive medications&#xD;
&#xD;
          6. Bleeding diathesis&#xD;
&#xD;
          7. Significant inter-current illness that will interfere with the radiation therapy&#xD;
             during the trial such as HIV infection, pulmonary compromise, active significant&#xD;
             alcohol abuse, active infection or febrile illness&#xD;
&#xD;
          8. Any history of myocardial infarction, congestive heart failure (NY Heart Association&#xD;
             Class 3 or 4), any history of ventricular arrhythmias, angina or active coronary heart&#xD;
             disease within 6 months.&#xD;
&#xD;
          9. Primary cancers of the nasal and paranasal cavities, and of the nasopharynx.&#xD;
&#xD;
         10. Evidence of distant metastases. If based on the best available clinical evidence the&#xD;
             investigator wishes to enroll the subject on trial, discussion and documentation with&#xD;
             one of the principal investigators is required.&#xD;
&#xD;
         11. Weight loss greater than 25% of usual body weight in the 3 months preceding trial&#xD;
             entry.&#xD;
&#xD;
         12. High risk for poor compliance with therapy or follow-up as assessed by investigator.&#xD;
&#xD;
         13. Pregnant or lactating women.&#xD;
&#xD;
         14. Prior radiation therapy to greater than 30% of the bone marrow&#xD;
&#xD;
         15. Prior experimental therapy for cancer within 30 days of entering the trial.&#xD;
&#xD;
         16. Prior radiation for head and neck cancer.&#xD;
&#xD;
         17. Patients with prior cancers, except: those diagnosed more than five years ago with no&#xD;
             evidence of disease recurrence and a clinical expectation of recurrence of less than&#xD;
             5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the&#xD;
             cervix. However, any patient with previous invasive breast cancer, prostate cancer or&#xD;
             melanoma is excluded.&#xD;
&#xD;
        Exclusion Criteria: Treatment group 2 (Cohorts 3 to 5) - Radiation, Sorafenib and&#xD;
        Cisplatin.&#xD;
&#xD;
          1. ECOG performance status 3 or 4&#xD;
&#xD;
          2. Absolute neutrophil count &lt;1.0 X 109/L, platelet count &lt;100 X 109/L or hemoglobin &lt;90&#xD;
             g/L.&#xD;
&#xD;
          3. Serum bilirubin ≥1.5 times ULN or AST/ALT ≥ 2.5 times ULN.&#xD;
&#xD;
          4. Calculated creatinine clearance (Cockcroft-Gault) &lt;55 mL/min. For patients in whom the&#xD;
             calculated creatinine clearance is borderline, GFR may be estimated by nuclear&#xD;
             renogram with the creatinine clearance ≥ 55 mL/min to be eligible.&#xD;
&#xD;
          5. Uncontrolled hypertension despite adequate anti-hypertensive medications&#xD;
&#xD;
          6. Bleeding diathesis&#xD;
&#xD;
          7. Significant inter-current illness that will interfere with the chemotherapy or&#xD;
             radiation therapy during the trial such as HIV infection, cardiac insufficiency,&#xD;
             pulmonary compromise, active significant alcohol abuse, active infection or febrile&#xD;
             illness,&#xD;
&#xD;
          8. Any history of myocardial infarction, any history of ventricular arrhythmias, angina&#xD;
             or active coronary heart disease within 6 months. Significant cardiac disease&#xD;
             resulting in an inability to tolerate the intravenous fluid load as required for&#xD;
             administration of cisplatin.&#xD;
&#xD;
          9. Primary cancers of the nasal and paranasal cavities, and of the nasopharynx.&#xD;
&#xD;
         10. Evidence of distant metastases. If based on the best available clinical evidence the&#xD;
             investigator wishes to enroll the subject on trial, discussion and documentation with&#xD;
             one of the principal investigators is required.&#xD;
&#xD;
         11. Symptomatic peripheral neuropathy ≥ grade 2.&#xD;
&#xD;
         12. Clinically significant sensori-neural hearing impairment which may be exacerbated by&#xD;
             cisplatin (audiometric abnormalities without corresponding clinical hearing impairment&#xD;
             will not be grounds for exclusion)&#xD;
&#xD;
         13. Weight loss greater than 20% of usual body weight in the 3 months preceding trial&#xD;
             entry.&#xD;
&#xD;
         14. High risk for poor compliance with therapy or follow-up as assessed by investigator.&#xD;
&#xD;
         15. Pregnant or lactating women.&#xD;
&#xD;
         16. Prior radiation therapy to greater than 30% of the bone marrow&#xD;
&#xD;
         17. Prior experimental therapy for cancer within 30 days of entering the trial.&#xD;
&#xD;
         18. Prior radiation for head and neck cancer.&#xD;
&#xD;
         19. Patients with prior cancers, except: those diagnosed more than five years ago with no&#xD;
             evidence of disease recurrence and a clinical expectation of recurrence of less than&#xD;
             5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the&#xD;
             cervix. However, any patient with previous invasive breast cancer, prostate cancer or&#xD;
             melanoma is excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Chia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <name_title>Dr Stephen Chia</name_title>
    <organization>British Columbia Cancer Agency</organization>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>head and neck</keyword>
  <keyword>Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

